S.Biomedics Co. Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of criti… Read more
Market Cap & Net Worth: S.Biomedics Co. Ltd. (304360)
S.Biomedics Co. Ltd. (KQ:304360) has a market capitalization of $284.71 Million (₩416.87 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #14830 globally and #424 in its home market, demonstrating a 2.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying S.Biomedics Co. Ltd.'s stock price ₩34900.00 by its total outstanding shares 11944796 (11.94 Million).
S.Biomedics Co. Ltd. Market Cap History: 2025 to 2026
S.Biomedics Co. Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $309.59 Million to $284.71 Million (0.00% CAGR).
S.Biomedics Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how S.Biomedics Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 304360 by Market Capitalization
Companies near S.Biomedics Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to S.Biomedics Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
S.Biomedics Co. Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, S.Biomedics Co. Ltd.'s market cap moved from $309.59 Million to $ 284.71 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩284.71 Million | -8.04% |
| 2025 | ₩309.59 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of S.Biomedics Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $284.71 Million USD |
| MoneyControl | $284.71 Million USD |
| MarketWatch | $284.71 Million USD |
| marketcap.company | $284.71 Million USD |
| Reuters | $284.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.